Ferroptosis: friend or foe in cancer immunotherapy?

Robin Demuynck; Iuliia Efimova; Elena Catanzaro; Dmitri V Krysko

doi:10.1080/2162402X.2023.2182992

Ferroptosis: friend or foe in cancer immunotherapy?

Oncoimmunology. 2023 Feb 23;12(1):2182992. doi: 10.1080/2162402X.2023.2182992. eCollection 2023.

Authors

Robin Demuynck^{1

2}, Iuliia Efimova^{1

2}, Elena Catanzaro^{1

2}, Dmitri V Krysko^{1

2}

Affiliations

¹ Cell Death Investigation and Therapy (CDIT) Laboratory, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
² Cancer Research Institute Ghent, Ghent, Belgium.

Abstract

Ferroptosis has gained interest due to it immunogenicity and the higher sensitivity of cancer cells to it. However, it was recently shown that ferroptosis in tumor-associated neutrophils leads to immunosuppression and negatively impacts therapy. Here, we discuss the potential implications of the two sides (friend versus foe) of ferroptosis in cancer immunotherapy.

Keywords: Immunogenic cell death; cancer immunosuppression; immunogenic ferroptosis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Ferroptosis*
Immunosuppression Therapy
Immunotherapy
Neoplasms*
Neutrophils

Grants and funding

This work was supported by the Research Foundation Flanders [11F7721N]; Research Foundation Flanders [11E3121N]; Research Foundation Flanders [The Excellence of Science (EOS) program 40007488]; Research Foundation Flanders [G016221N, G043219N]; Special Research Fund (BOF) of Ghent University [BOF/IOP01/O3618, BOF/IOP/2022/033, BOF23/GOA/029].